Lasmiditan in the treatment of migraine attacks

Marcin Kopka

Affiliation and address for correspondence
Aktualn Neurol 2019, 19 (4), p. 179–182
DOI: 10.15557/AN.2019.0025

Triptans are the drugs of choice in moderate to severe migraine attacks. It is estimated that they are ineffective in one-third of patients. Moreover, triptans are contraindicated in patients with cardiovascular diseases. Therefore, there is a need for novel antimigraine treatments devoid of vasoconstrictor activity. The aim of this review paper is to report current data on 5HT1F agonist – lasmiditan. Its efficacy was confirmed in randomized controlled trails – SAMURAI, SPARTAN and GLADIATOR. The percentages of patients free of migraine pain and migraine bothersome symptoms were higher in the group treated with lasmiditan compared to placebo. Generally, lasmiditan has a favourable safety profile. Dizziness was the most frequently reported adverse event. No toxic effects on the liver or negative effects on hemodynamic or laboratory parameters were reported. The discontinuation rate due to adverse events in patients treated with lasmiditan was low. According to the available data, lasmiditan is safe, efficacious and well tolerated in treating migraine attacks. Lasmiditan does not exhibit vasoconstrictive proprieties and may be used in patients with cardiovascular diseases, in whom triptans are contraindicated. The results of studies on effectiveness and tolerability of lasmiditan are promising and it is hoped that in the future it will expand abortive therapeutic options for migraine. In October 2019, lasmiditan was approved by the US Food and Drug Administration for the treatment of migraine attacks in adult patients. Currently this drug in not available in Poland.

migraine, CGRP, treatment, ditans

Oświadczam, że posiadam prawo wykonywania zawodu lekarza i jestem uprawniony do otrzymywania specjalistycznych informacji medycznych. Chcę zapoznać się z informacją z serwisu.